Megan Lancaster
Has grant
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Open
A Regulatory-First Framework to Reveal Noncoding Cardiomyopathy
Open Date: 2026-07-01
Close Date: 2028-06-30
Grant: Open
A high-throughput, multimodal strategy to improve variant classification
Open Date: 2025-01-03
Close Date: 2029-12-31
Articles (8)
Year:
2026
Year:
2026
Year:
2025
Variants in the familial hypercholesterolemia gene LDLR —the most important genetic driver of cardiovascular disease—can raise circulating low-density lipoprotein (LDL) cholesterol concentrations and increase the risk of premature atherosclerosis. Definitive classifications are lacking for nearly half of clinically encountered LDLR missense variants, limiting interventions that reduce disease burden. We tested the impact of ~17,000 (nearly all possible) LDLR coding variants on both LDLR cell-surface abundance and LDL uptake, yielding sequence–function maps that recapitulate known biochemistry, offer functional insights, and provide evidence for interpreting clinical variants. Functional scores correlated with hyperlipidemia phenotypes in prospective human cohorts and augmented polygenic scores to improve risk inference, highlighting the potential of this resource to accelerate familial hypercholesterolemia diagnosis and improve patient outcomes.
Year:
2025
Year:
2024
Year:
2024
Background Drug-induced QT interval prolongation raises the risk of fatal arrhythmia and is a central issue in safety pharmacology. Yet individual QT drug response is highly variable, and risk stratification remains a challenge. We hypothesized that genetic factors underlying the baseline QT influence this variation in QT drug response. Methods A cohort of 990 healthy subjects was prospectively challenged with a single 80 mg oral sotalol dose. Exclusion criteria included abnormal ECG, cardiac disease, and QT-prolonging drug use. ECGs were obtained at baseline and 3 hours post-dose. QT response was defined as absolute change in Fridericia heart-rate corrected QT (ΔQTc). Plasma sotalol was measured 3 hours post-dose. Subjects were genotyped on the MEGA array. Principal component analysis of genotypes was used to define genetic ancestry. A polygenic risk score (PRS) for the baseline QTc comprised of 465,399 common variants was calculated from assayed and imputed genotypes. The difference in PRS between subjects with high QT response (ΔQTc≥60 ms) and those with ΔQTc<60ms was assessed by Mann Whitney test. A multivariable regression model was used to assess the association between PRS and ΔQTc after covariate adjustment. Results: Of the 990 subjects, 978 (99%) passed genomic quality control and were included in analysis. 62% were female (n=607), with median age 23 (interquartile range (IQR) 21-33). The median ΔQTc 3 hours post-sotalol was 21 ms (IQR 12-30). Ten subjects (1%) had ΔQTc≥60 ms, and their PRS was significantly higher compared to those with ΔQTc<60 ms (P=0.0082). In the regression model, PRS was positively associated with ΔQTc (P=0.0002). Conclusion Common genetic variants associated with the baseline QT also capture part of the repolarization response to sotalol. This adds to the emerging concept that the genetic architecture of a trait can predict drug response.
Year:
2024
Background We identified a novel SCN5A variant, E171Q, in a neonate with very frequent ectopy and reduced ejection fraction which normalized after arrhythmia suppression by flecainide. This clinical picture is consistent with multifocal ectopic Purkinje-related premature contractions (MEPPC). Most previous reports of MEPPC have implicated SCN5A variants such as R222Q that neutralize positive charges in the S4 voltage sensor helix of the channel protein Na V 1.5 and generate a gating pore current. Methods and Results E171 is a highly conserved negatively-charged residue located in the S2 transmembrane helix of Na V 1.5 domain I. E171 is a key component of the Gating Charge Transfer Center, a region thought to be critical for normal movement of the S4 voltage sensor helix. We used heterologous expression, CRISPR-edited induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs), and molecular dynamics simulations to demonstrate that E171Q generates a gating pore current, which was suppressed by a low concentration of flecainide (IC50 = 0.71±0.07 µM). R222Q shifts voltage dependence of activation and inactivation in a negative direction but we observed positive shifts with E171Q. E171Q iPSC-CMs demonstrated abnormal spontaneous activity and prolonged action potentials. Molecular dynamics simulations revealed that both R222Q and E171Q proteins generate a water-filled permeation pathway that underlies generation of the gating pore current. Conclusion Previously identified MEPPC-associated variants that create gating pore currents are located in positively-charged residues in the S4 voltage sensor and generate negative shifts in the voltage dependence of activation and inactivation. We demonstrate that neutralizing a negatively charged S2 helix residue in the Gating Charge Transfer Center generates positive shifts but also create a gating pore pathway. These findings implicate the gating pore pathway as the primary functional and structural determinant of MEPPC and widen the spectrum of variants that are associated with gating pore-related disease in voltage-gated ion channels.
Year:
2024
Collaborators (23)
Matthew O'Neill
Brigham and Women's Hospital
Simon Georg Pfisterer
University of Helsinki
Eric Smith
University of Michigan
Robert Hegele
Jacob J. Wolfe Distinguished Medical Research Chair in Human Gene Function
Western University
Julia Cadrin-Tourigny
Clinical Assistant Professor
Université de Montréal
Kenneth Matreyek
Assistant Professor
Case Western Reserve University
Mafalda Bourbon
Invited Professor
Faculty of Medicine, University of Lisbon
Qianru Wang
Associate Professor (non-tenured)
Shanghai Jiao Tong University
Dan M Roden
Professor
Vanderbilt University Medical Center
Adam Helms
Assistant Professor
University of Michigan
Andrew Glazer
Assistant Professor
Vanderbilt University Medical Center
Joe-Elie Salem
Professor of Medicine and Pharmacology
Assistance Publique - Hôpitaux de Paris
Melina Claussnitzer
Assistant Professor
Harvard University
Nosheen Reza
University of Pennsylvania
Christian Funck-Brentano
Emeritus Professor / Delegate Research Integrity Officer
Sorbonne Université
Frederick Roth
Professor and Chair
University of Pittsburgh
Kristen Medo
Research Services Professional
University of Colorado Anschutz Medical Campus
Yuko Wada
-
David Samuels
Associate Professor
Vanderbilt University
Shubhayan Sanatani
Professor
The University of British Columbia
Perry Elliott
University College London
Douglas Fowler
Professor
University of Washington
Calum MacRae
Professor
Harvard University
Make your next move.
Prepare your application
Review drafts before you send them.